Cargando…

Advances in targeted therapy for acute myeloid leukemia

Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than half of a century. Although much progress has been made toward improving treatment related mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jifeng, Jiang, Peter Y. Z., Sun, Hao, Zhang, Xia, Jiang, Zhongxing, Li, Yingmei, Song, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238648/
https://www.ncbi.nlm.nih.gov/pubmed/32477567
http://dx.doi.org/10.1186/s40364-020-00196-2
_version_ 1783536575965036544
author Yu, Jifeng
Jiang, Peter Y. Z.
Sun, Hao
Zhang, Xia
Jiang, Zhongxing
Li, Yingmei
Song, Yongping
author_facet Yu, Jifeng
Jiang, Peter Y. Z.
Sun, Hao
Zhang, Xia
Jiang, Zhongxing
Li, Yingmei
Song, Yongping
author_sort Yu, Jifeng
collection PubMed
description Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than half of a century. Although much progress has been made toward improving treatment related mortality rate in the past few decades, long term overall survival has stagnated. Exciting developments of gene mutation-targeted therapeutic agents are now changing the landscape in AML treatment. New agents offer more clinical options for patients and also confer a more promising outcome. Since Midostaurin, a FLT3 inhibitor, was first approved by US FDA in 2017 as the first gene mutation-targeted therapeutic agent, an array of new gene mutation-targeted agents are now available for AML treatment. In this review, we will summarize the recent advances in gene mutation-targeted therapies for patients with AML.
format Online
Article
Text
id pubmed-7238648
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72386482020-05-29 Advances in targeted therapy for acute myeloid leukemia Yu, Jifeng Jiang, Peter Y. Z. Sun, Hao Zhang, Xia Jiang, Zhongxing Li, Yingmei Song, Yongping Biomark Res Review Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than half of a century. Although much progress has been made toward improving treatment related mortality rate in the past few decades, long term overall survival has stagnated. Exciting developments of gene mutation-targeted therapeutic agents are now changing the landscape in AML treatment. New agents offer more clinical options for patients and also confer a more promising outcome. Since Midostaurin, a FLT3 inhibitor, was first approved by US FDA in 2017 as the first gene mutation-targeted therapeutic agent, an array of new gene mutation-targeted agents are now available for AML treatment. In this review, we will summarize the recent advances in gene mutation-targeted therapies for patients with AML. BioMed Central 2020-05-20 /pmc/articles/PMC7238648/ /pubmed/32477567 http://dx.doi.org/10.1186/s40364-020-00196-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yu, Jifeng
Jiang, Peter Y. Z.
Sun, Hao
Zhang, Xia
Jiang, Zhongxing
Li, Yingmei
Song, Yongping
Advances in targeted therapy for acute myeloid leukemia
title Advances in targeted therapy for acute myeloid leukemia
title_full Advances in targeted therapy for acute myeloid leukemia
title_fullStr Advances in targeted therapy for acute myeloid leukemia
title_full_unstemmed Advances in targeted therapy for acute myeloid leukemia
title_short Advances in targeted therapy for acute myeloid leukemia
title_sort advances in targeted therapy for acute myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238648/
https://www.ncbi.nlm.nih.gov/pubmed/32477567
http://dx.doi.org/10.1186/s40364-020-00196-2
work_keys_str_mv AT yujifeng advancesintargetedtherapyforacutemyeloidleukemia
AT jiangpeteryz advancesintargetedtherapyforacutemyeloidleukemia
AT sunhao advancesintargetedtherapyforacutemyeloidleukemia
AT zhangxia advancesintargetedtherapyforacutemyeloidleukemia
AT jiangzhongxing advancesintargetedtherapyforacutemyeloidleukemia
AT liyingmei advancesintargetedtherapyforacutemyeloidleukemia
AT songyongping advancesintargetedtherapyforacutemyeloidleukemia